Melatonin and coronary artery disease;Melatonina y aterosclerosis coronaria

Clinica e Investigacion en Arteriosclerosis

Volumn 21, Issue 5, 2009, Pages 247-256

  Domínguez Rodríguez, Alberto ^a   Samimi Fard, Sima ^a   Abreu González, Pedro ^b   Carlos Kaski, Juan ^c  

^a HOSPITAL UNIVERSITARIO DE CANARIAS   (Spain)

^b UNIVERSIDAD DE LA LAGUNA   (Spain)

^c Departamento de Ciencias Cardiológicas St George's Hospital Londres Reino Unido   (United Kingdom)

Author keywords

Antioxidant therapy; Atherosclerosis; Melatonin; Oxidative stress

Indexed keywords

FREE RADICAL; MELATONIN;

ANTIHYPERTENSIVE ACTIVITY; ANTIINFLAMMATORY ACTIVITY; ANTIOXIDANT ACTIVITY; ATHEROSCLEROSIS; CELL DAMAGE; CORONARY ARTERY DISEASE; DISEASE ASSOCIATION; IMMUNOMODULATION; INFLAMMATION; METABOLISM; REPERFUSION INJURY; REVIEW; SYNTHESIS;

EID: 70549097017     PISSN: 02149168     EISSN: 15781879     Source Type: Journal    
DOI: 10.1016/S0214-9168(09)72688-9     Document Type: Review

References (112)

1. Lerner A.B., Case J.D., and Takahashi Y. Isolation of melatonin, a pineal factor that lightens melanocytes. J Am Chem Soc 80 (1958) 2587
2. Claustrat B., Brun J., and Chazot G. The basic physiology and pathophysiology of melatonin. Sleep Med Rev 9 (2005) 11-24
3. Reiter R.J. Pineal melatonin: cell biology of its synthesis and of its physiological interactions. Endocr Rev 12 (1991) 151-180
4. Ribelayga C., Pevet P., and Simmoneaux V. HIOMT drives the photoperiodic changes in the amplitude of the melatonin peak of the Siberian hamster. Am J Physiol Regul Integr Comp Physiol 278 (2000) R1339-R1345
5. Ceinos R.M., Chansard M., Revel F., Calgari C., Miguez J.M., and Simmoneaux V. Analysis of adrenergic regulation of melatonin synthesis in Siberian hamster pineal emphasizes the role of HIOMT. Neurosignals 13 (2004) 308-317
6. Iuvone P.M., and Besharse J.C. Regulation of indoleamine N-acetyltransferase activity in the retina: effects of light and dark, protein synthesis inhibitors and cyclic nucleotide analogs. Brain Res 273 (1983) 111-119
7. Martin X.D., Malina H.Z., Brennan M.C., Hendrickson P.H., and Lichter P.R. The ciliary body - the third organ found to synthesize indoleamines in humans. Eur J Ophtalmol 2 (1992) 67-72
8. Abe M., Itoh M.T., Miyata M., Ishikawa S., and Sumi Y. Detection of melatonin, its precursors and related enzyme activities in rabbit lens. Exp Eye Res 68 (1999) 255-262
9. Menendez-Pelaez A., Howes K.A., Gonzalez-Brito A., and Reiter R.J. Nacetyltransferase activity, hydroxyindole-O-methyltransferase activity, and melatonin levels in the Harderian glands of the female Syrian hamster: changes during the light:dark cycle and the effect of 6-parachlorophenylalanine administration. Biochem Biophys Res Commun 145 (1987) 1231-1238
10. Stefulj J., Hörtner M., Ghosh M., Schauenstein K., Rinner I., Wölfler A., et al. Gene expression of the key enzymes of melatonin synthesis in extrapineal tissues of the rat. J Pineal Res 30 (2001) 243-247
11. Jimenez-Jorge S., Jimenez-Caliani A.J., Guerrero J.M., Naranjo M.C., Lardone P.J., Carrillo-Vico A., et al. Melatonin synthesis and melatonin-membrane receptor (MT1) expression during rat thymus development: role of the pineal gland. J Pineal Res 39 (2005) 77-83
12. Kvetnoy I.M. Extrapineal melatonin: location and role within diffuse neuroendocrine system. Histochem J 31 (1999) 1-12
13. Tan D.X., Manchester L.C., Reiter R.J., Qi W.B., Zhang M., Weintraub S.T., et al. Identification of highly elevated levels of melatonin in bone marrow: its origin and significance. Biochim Biophys Acta 1472 (1999) 206-214
14. Conti A., Conconi S., Hertens E., Skwarlo-Sonta K., Markowska M., and Maestroni J.M. Evidence for melatonin synthesis in mouse and human bone marrow cells. J Pineal Res 28 (2000) 193-202
15. Huether G., Poeggeler B., Reimer A., and George A. Effect of tryptophan administration on circulating melatonin levels in chicks and rats: evidence for stimulation of melatonin synthesis and release in the gastrointestinal tract. Life Sci 51 (1992) 945-953
16. Huether G. The contribution of extrapineal sites of melatonin synthesis to circulating melatonin levels in higher vertebrates. Experientia 49 (1993) 665-670
17. Itoh M.T., Ishizuha B., Kuribayashi Y., Amemiya A., and Sumi Y. Melatonin, its precursors, and synthesizing enzyme activities in the human ovary. Mol Hum Reprod 5 (1999) 402-408
18. Tijmes M., Pedraza R., and Valladares L. Melatonin in the rat testis: evidence for local synthesis. Steroids 61 (1996) 65-68
19. Iwasaki S., Nakazawa K., Sakai J., Kometani K., Iwashita M., Yoshimura Y., et al. Melatonin as a local regulator of human placental function. J Pineal Res 39 (2005) 261-265
20. Carrillo-Vico A., Calvo J.R., Abreu P., Lardone P.J., García-Mauriño S., Reiter R.J., et al. Evidence of melatonin synthesis by human lymphocytes and its physiological significance: possible role as intra-crine, autocrine and/or paracrine substance. FASEB J 18 (2004) 537-539
21. Fischer T.W., Sweatman T.W., Semak I., Sayre R.M., Wortsman J., and Slominski A. Constitutive and UV-induced metabolism of melatonin in keratinocytes and cell-free systems. FASEB J 20 (2006) 1564-1566
22. Tan D.X., Manchester L.C., Hardeland R., Lopez-Burillo S., Mayo J.C., Sainz R.M., et al. Melatonin: a hormone, a tissue factor, an autocoid, a paracoid, and an antioxidant vitamin. J Pineal Res 34 (2003) 75-78
23. Lahiri D.K., Davis D., and Nurnberger Jr. J.I. Detection of specific protein bands with melatonin-like immunoreactivity in different cell lines and human brain regions. IUBMB Life 48 (1999) 127-132
24. Cardinali D.P. Melatonin. A mammalian pineal hormone. Endocr Rev 2 (1981) 327-346
25. Markey S.P., Higa S., Shih M., Danforth D.N., and Tamarkin L. The correlation between human plasma melatonin levels and urinary 6-hydroxymelatonin excretion. Clin Chim Acta 150 (1985) 221-225
26. Ma X., Idle J.R., Krausz K.W., and Gonzalez F.J. Metabolism of melatonin by human cytochromes p450. Drug Metab Dispos 33 (2005) 489-494
27. Zhang H., Squadrito G.L., and Pryor W.A. The reaction of melatonin with peroxynitrite: formation of melatonin radical cation and absence of stable nitrated products. Biochem Biophys Res Commun 251 (1998) 83-87
28. Zhang H., Squadrito G.L., Uppu R., and Pryor W.A. Reaction of peroxynitrite with melatonin: a mechanistic study. Chem Res Toxicol 12 (1999) 526-534
29. Horstmann J.A., Wrona M.Z., and Dryhurst G. Further insights into the reaction of melatonin with hydroxyl radical. Bioorg Chem 30 (2002) 371-382
30. Tan D.X., Manchester L.C., Reiter R.J., Plummer B.F., Hardies L.J., Weintraub S.T., et al. A novel melatonin metabolite, cyclic 3-hydroximelatonin: A biomarker of melatonin interaction with hydroxyl radicals. Biochem Biophys Res Commun 253 (1998) 614-620
31. Peyrot F., Houée-Levin C., and Ducrocq C. Melatonin nitrosation promoted by NO*2; comparison with the peroxynitrite reaction. Free Radic Res 40 (2006) 910-920
32. Semak I., Naumova M., Korik E., Terekhovich V., Wortsman J., and Slominski A. A novel metabolic pathway of melatonin: oxidation by cytochrome C. Biochemistry 44 (2005) 9300-9307
33. Matuszak Z., Bilska M.A., Reszka K.J., Chignell C.F., and Bilski P. Interaction of singlet molecular oxygen with melatonin and related indoles. Photochem Photobiol 78 (2003) 449-455
34. Maharaj D.S., Limson J.L., and Daya S. Hydroxymelatonin converts Fe(III) to Fe(II) and reduces iron-induced lipid peroxidation. Life Sci 72 (2003) 1367-1375
35. Liu X., Chen Z., Chua C.C., Ma Y.S., Youngberg G.A., Hamdy R., et al. Melatonin as an effective protector against doxorrubicin-induced cardiotoxicity. Am J Physiol Heart Circ Physiol 283 (2002) H254-H263
36. Lahiri D.K., Chen D.M., Lahiri P., Bondy S., and Greig N.H. Amyloid, cholinesterase, melatonin, and metals and their roles in aging and neurodegenerative diseases. Ann N Y Acad Sci 1056 (2005) 430-449
37. Maharaj D.S., Anoopkumar-Dukie S., Glass B.D., Antunes E.M., Lack B., Walker R.B., et al. The identification of the UV degradants of melatonin and their ability to scavenge free radicals. J Pineal Res 32 (2002) 257-261
38. Srinivasan V., Pandi-Perumal S.R., Cardinali D.P., Poeggeler B., and Hardeland R. Melatonin in Alzheimer's disease and other neurodegenerative disorders. Behav Brain Funct 2 (2006) 1-23
39. Tan D.X., Manchester L.C., Burkhardt S., Sainz R.M., Mayo J.C., Kohen R., et al. N1-acetyl-N2-formyl-5-methoxykynuramine, a biogenic amine and melatonin metabolite, functions as a potent antioxidant. FASEB J 15 (2001) 2294-2296
40. Burkhardt S., Reiter R.J., Tan D.X., Hardeland R., Cabrera J., and Karbownik M. DNA oxidatively damaged by chromium(III) and H2O2 is protected by the antioxidants melatonin, N1-acetyl-N2-formyl-5-methoxykynuramine, resveratrol and uric acid. Int J Biochem Cell Biol 33 (2001) 775-783
41. Onuki J., Almeida E.A., Medeiros M.H., and Di Mascio P. Inhibition of 5-aminolevulinic acid-induced DNA damage by melatonin, N1-acetyl-N2-formyl-5-methoxykynuramine, quercetin or resveratrol. J Pineal Res 38 (2005) 107-115
42. Ressmeyer A.R., Mayo J.C., Zelosko V., Sainz R.M., Tan D.X., Poeggeler B., et al. Antioxidant properties of the melatonin metabolite N1- acetyl-5-methoxykynuramine (AMK): scavenging of free radicals and prevention of protein destruction. Redox Rep 8 (2003) 205-213
43. Entrena A., Camacho M.E., Carrion M.D., López-Cara L.C., Velasco G., León J., et al. Kynurenamines as neural nitric oxide synthase inhibitors. J Med Chem 48 (2005) 8174-8181
44. Leon J., Escames G., Rodriguez M.I., López L.C., Tapias V., Entrena A., et al. Inhibition of neuronal nitric oxide synthase activity by N1- acetyl-5-methoxykynuramine, a brain metabolite of melatonin. J Neurochem 98 (2006) 2023-2033
45. Kelly R.W., Amato F., and Seamark R.F. N-acetyl-5-methoxykynurenamine, a brain metabolite of melatonin, is a potent inhibitor of prostaglandin biosynthesis. Biochem Biophys Res Commun 121 (1984) 372-379
46. Mayo J.C., Sainz R.M., Tan D.X., Hardeland R., Leon J., Rodriguez C., et al. Anti-inflammatory actions of melatonin and its metabolites, N1-acetyl-N2-formyl-5-methoxykynuramine (AFMK) and N1-acetyl-5-methoxykynuramine (AMK), in macrophages. J Neuroimmunol 165 (2005) 139-149
47. Benitez-King G., and Anton-Tay F. Calmodulin mediates melatonin cytoskeletal effects. Experientia 49 (1993) 635-641
48. Sanchez-Barcelo E.J., Cos S., Mediavilla D., Martínez-Campa C., González A., and Alonso-González C. Melatonin-estrogen interactions in breast cancer. J Pineal Res 38 (2005) 217-222
49. Smirnov A.N. Nuclear melatonin receptors. Biochemistry 66 (2001) 19-26
50. Hirose T., Smith R.J., and Jetten A.M. ROR gamma: the third member of ROR/RZR orphan receptor subfamily that is highly expressed in skeletal muscle. Biochem Biophys Res Commun 205 (1994) 1976-1983
51. Steinhilber D., Brungs M., Werz O., Wiesenberg I., Danielsson C., Kahlen J.P., et al. The nuclear receptor for melatonin represses 5-lipoxygenase gene expression in human B lymphocytes. J Biol Chem 270 (1995) 7037-7040
52. Garcia-Maurino S., Gonzalez-Haba M.G., Calvo J.R., Goberna R., and Guerrero J.M. Involvement of nuclear binding sites for melatonin in the regulation of IL-2 and IL-6 production by human blood mononuclear cells. J Neuroimmunol 92 (1998) 76-84
53. Carrillo-Vico A., Lardone P.J., Fernandez-Santos J.M., Martin-Lacave, Calvo J.R., Karasek M., et al. Human lymphocyte-synthesized melatonin is involved in the regulation of the interleukin-2/interleukin-2 receptor system. J Clin Endocrinol Metab 90 (2005) 992-1000
54. Dubocovich M.L., Rivera-Bermudez M.A., Gerdin M.J., and Masana M.I. Molecular pharmacology, regulation and function of mammalian melatonin receptors. Front Biosci 8 (2003) d1093-d1108
55. Ekmekcioglu C., Thalhammer T., Humpeler S., Mehrabi M.R., Glogar H.D., Hölzenbein T., et al. The melatonin receptor subtype MT2 is present in the human cardiovascular system. J Pineal Res 35 (2003) 40-44
56. Ekmekcioglu C., Haslmayer P., Philipp C., Mehrabi M.R., Glogar H.G., Grimm M., et al. 24h variation in the expression of the mt1 melatonin receptor subtype in coronary arteries derived from patients with coronary heart disease. Chronobiol Int 18 (2001) 973-985
57. Ekmekcioglu C., Haslmayer P., Philipp C., Mehrabi M.R., Glogar H.D., Grimm M., et al. Expression of the MT1 melatonin receptor subtype in human coronary arteries. J Recept Signal Transduct Res 21 (2001) 85-91
58. Dubocovich M.L., and Markowka M. Functional MT1 and MT2 melatonin receptors in mammals. Endocrine 27 (2005) 101-110
59. Ebisawa T., Uchiyama M., Kajimura N., Kamei Y., Shibui K., Kudo Y., et al. Genetic polymorphisms of human melatonin 1b receptor gene in circadian rythm sleep disorders and controls. Neurosci Lett 280 (2000) 29-32
60. Ebisawa T., Kajimura N., Uchiyama M., Katoh M., Sekimoto M., Watanabe T., et al. Alleic variants of human melatonin 1a receptor: function and prevalence in subjects with circadian rythm sleep disorders. Biochem Biophys Res Commun 262 (1999) 832-837
61. García-Moll X., and Kaski J.C. Cardiopatía isquémica: marcadores de inflamación y riesgo cardiovascular. Rev Esp Cardiol 52 (1999) 990-1003
62. Pérez Fernández R., and Kaski J.C. Interleucina-10 y enfermedad coronaria. Rev Esp Cardiol 55 (2002) 738-750
63. García-Moll X. Fisiopatología y marcadores del síndrome coronario agudo sin elevación del segmento ST. Rev Esp Cardiol Supl 5 (2005) 8C-14C
64. Reiter R.J., Calvo J.R., Karbownik M., Qi W., and Tan D.X. Melatonin and its relation to the immune system and inflammation. Ann N Y Acad Sci 917 (2000) 376-386
65. Carrillo-Vico A., Guerrero J.M., Lardone P.J., and Reiter R.J. A review of the multiple actions of melatonn on the immune system. Endocrine 27 (2005) 189-200
66. Brugger P., Marktl W., and Herold M. Impaired nocturnal secretion of melatonin in coronary heart disease. Lancet 345 (1995) 1408
67. Sakotnik A., Liebmann P., Stoschitzki K., Lercher P., Schauenstein K., Klein W., et al. Decreased melatonin synthesis in patients with coronary artery disease. Eur Heart J 20 (1999) 1314-1317
68. Girotti L., Lago M., Ianovsky O., Elizari M.V., Lloret S.P., Albornoz L.E., et al. Low urinary 6-sulfatoxymelatonin levels in patients with severe congestive heart failure. Endocrine 22 (2003) 245-248
69. Altun A., Yaprak M., Aktoz M., Vardar A., Betul U.A., and Olzbay G. Impaired nocturnal synthesis of melatonin in patients with cardiac syndrome X. Neurosci Lett 327 (2002) 143-145
70. Dominguez-Rodriguez A., Abreu-Gonzalez P., Garcia M., Sánchez J., Marrero F., and Armas-Trujillo D. Decreased nocturnal melatonin levels during acute myocardial infarction. J Pineal Res 33 (2002) 248-252
71. Reiter R.J., and Tan D.X. Melatonin: a novel protective agent against oxidative injury of the ischemic / reperfused heart. Cardiovasc Res 58 (2003) 10-19
72. Reiter R.J., Tan D.X., Manchester L.C., and Qi W. Biochemical reactivity of melatonin with reactive oxygen and nitrogen species: a review of the evidence. Cell Biochem Biophys 34 (2001) 237-256
73. Cuzzocrea S., Zingarelli B., Gilad E., Hake P., Salzman A.L., and Szabo C. Protective effect of melaonin in carrageenan-induced models of local inflammation: relationship to its inhibitory effect on nitric oxide production and its peroxynitrite scavenging activity. J Pineal Res 23 (1997) 106-116
74. Dominguez-Rodriguez A., Abreu-Gonzalez P., Garcia-González M., Ferrer-Hita J., Vargas M., and Reiter R.J. Elevated levels of oxidized lowdensity lipoprotein and impaired nocturnal synthesis of melatonin in patients with myocardial infarction. Atherosclerosis 180 (2005) 101-105
75. Garcia-Moll X. Marcadores de inflamación y de antiinflamación en el síndrome coronario agudo: ¿listos para usarlos en la práctica clínica?. Rev Esp Cardiol 58 (2005) 615-617
76. Rodríguez J.A., Orbe J., and Páramo J.A. Metaloproteasas, remodelado vascular y síndromes aterotrombóticos. Rev Esp Cardiol 60 (2007) 959-967
77. Domínguez Rodríguez A., Abreu González P., García González M.J., De la Rosa A., Vargas M., and Marrero F. Ritmo luz / oscuridad de las citocinas proinflamatorias en el infarto agudo de miocardio. Rev Esp Cardiol 56 (2003) 555-560
78. Domínguez Rodríguez A., Abreu González P., Garcia M., Ferrer J., De la Rosa A., Vargas M., et al. Light / dark patterns of interleukin - 6 in relation to the pineal hormone melatonin in patients with acute myocardial infarction. Cytokine 26 (2004) 89-93
79. Domínguez Rodríguez A., García González M.J., and Abreu González P. Light/dark cycle variations in proinflammatory cytokines in acute coronary síndromes. Rev Esp Cardiol 57 (2004) 1250
80. Dominguez Rodriguez A., Garcia Gonzalez M.J., Abreu Gonzalez P., Ferrer J., and Kaski J.C. Relation of nocturnal melatonin levels to Creactive protein concentration in patients with ST-segment elevation myocardial infarction. Am J Cardiol 97 (2006) 10-12
81. Domínguez Rodríguez A., Kaski J.C., Abreu-González P., and García González M.J. Cinética de la proteína C reactiva: importancia del ritmo luz/oscuridad de la proteína C reactiva en el síndrome coronario agudo. Rev Esp Cardiol 59 (2006) 1204-1205
82. Dominguez-Rodriguez A., Abreu-Gonzalez P., Garcia-Gonzalez M.J., and Reiter R.J. Relation of nocturnal melatonin levels to serum matriz metalloproteinase-9 concentrations in patients with myocardial infarction. Thromb Res 120 (2007) 361-366
83. Dominguez-Rodriguez A., Kaski J.C., Abreu-Gonzalez P., and Garcia-Gonzalez M.J. The kinetics of metalloproteinase-9: the significance of the light-dark cycle in metalloproteinase-9 in acute coronary syndrome. Rev Esp Cardiol 61 (2008) 327
84. Dominguez-Rodriguez A., Abreu-Gonzalez P., Garcia-Gonzalez M.J., Samimi-Fard S., Kaski J.C., and Reiter R.J. Light/dark patterns of soluble vascular cell adhesión molecule-1 in relatino to melatonin in patients with ST-segment elevation myocardial infarction. J Pineal Res 44 (2008) 65-69
85. Vilar-Rojas C., Guzmán-Grenfell A.M., and Hicks J.J. Participation of oxygen-free radicals in the oxido-reduction of proteins. Arch Med Res 27 (1996) 1-6
86. Férez Santander S.M., Márquez M.F., Peña Duque M.A., Ocaranza Sánchez R., De la Peña Almaguer E., and Eid Lidt G. Myocardial reperfusión injury. Rev Esp Cardiol 57 Supl 1 (2004) 9-21
87. De Scheerder I.K., VandeKraay A.M.M., Lamers J.M.J., Koster J.F., De Jong J.F., and Serruys P.W. Myocardial malondialdehyde and uric acid release after short-lasting coronary occlusions during coronary angioplasty: potential mechanisms for free radical generation. Am J Cardiol 68 (1991) 392-395
88. Sahna E., Omez E., and Acet A. Effects of physiological and pharmacological concentrations of melatonin on ischemia-reperfusion arrhythmias in rats: Can the incidence of complete suden cardiac death be reduced?. J Pineal Res 32 (2002) 194-198
89. Sahna E., Acet A., Ozer M.K., and Olmez E. Myocardial ischemia-reperfusion in rats: reduction of infarct size by either supplemental physiological or pharmacological doses of melatonin. J Pineal Res 33 (2002) 234-238
90. Kaneko S., Okumura K., Numaguchi Y., Matsui H., Murase K., Moruno S., et al. Melatonin scavenges hydroxil radical and protects isolated rat hearts from ischemic reperfusión injury. Life Sci 67 (2000) 101-112
91. Sahna E., Parlakpinar H., Turkoz Y., and Acet A. Protective effects of melatonin on myocardial ischemia/reperfusion induced infarct size and oxidative changes. Physiol Res 54 (2005) 491-495
92. Lagneux C., Joyeux M., Demenge P., Ribuot C., and Godin-Ribuot D. Protective effects of melatonin against ischemia-reperfusion injury in the isolated rat heart. Life Sci 66 (2000) 503-509
93. Bardají A., Alonjo J., García-Moll X., and Bueno H. [Ischemic heart disease: 2005 update]. Rev Esp Cardiol 59 Supl 1 (2006) 3-19
94. Dominguez-Rodriguez A., Abreu-Gonzalez P., Garcia-Gonzalez M.J., Samimi-Fard S., Reiter R.J., and Kaski J.C. Association of ischemia-modified albumin and melatonin in patients with ST-elevation myocardial infarction. Atherosclerosis 199 (2008) 73-78
95. Dugo L., Serriano I., Fulia F., De Sarro A., Caputi A.P., and Cuzzocrea S. Effect of melatonin on cellular energy depletion mediated by peroxynitrite and poly (ADP-ribose) synthetase activation in an acute model of inflammation. J Pineal Res 31 (2001) 76-84
96. Zhang H., Squadrito G.L., and Pryor W.A. The reaction of melatonin with peroxynitrite: Formation of melatonin radical cation and absence of stable nitrated products. Biochem Biophys Res Commun 251 (1998) 83-87
97. Blanchard B., Pompon D., and Ducroq C. Nitrosation of melatonin by nitric oxide and peroxynitrite. J Pineal Res 29 (2000) 184-192
98. Reiter R.J., Tan D.X., Osuna C., and Gitto E. Actions of melatonin in the reduction of oxidative stress. J Biomed Sci 7 (2000) 444-458
99. Urata Y., Honma S., Goto S., Todoroki S., Lida T., Cho S., et al. Melatonin induces γ-glutamylcysteine synthetase mediated by activator protein-1 in human vascular endotelial cells. Free Radic Biol Med 27 (1999) 838-847
100. Acuña-Castroviejo D., Martin M., Macias M., Escames G., Leon J., Khaldy H., et al. Melatonin, mitochondria and cellular bioenergetics. J Pineal Res 30 (2001) 65-74
101. Reiter R.J., Tan D.X., Manchester L.C., and El-sawi M.R. Melatonin reduces oxidant damage and promotes mitochondrial respiration: implications for aging. Ann N Y Acad Sci 959 (2002) 238-250
102. Lee B.J., Parrot K.A., Ayre J.W., and Sack R.L. Preliminary evaluation of transdermal delivery of melatonin in human subjects. Res Comun Mol Pathol Pharmacol 85 (1994) 337-346
103. Van de Heuvel C., Kennaway D.J., and Dawson D. Effects of daytime melatonin infusion in young adults. Am J Physiol 275 (1998) E19-E26
104. Van de Heuvel C., Kennaway D.J., and Dawson D. Termoregulatory and soporific effects of very low dose melatonin injection. Am J Physiol 39 (1999) E249-E254
105. Mallo C., Zaidan R., Galy G., Vermeulen E., Brun J., Chazot G., et al. Pharmacokinetics of melatonin in man after intravenous infusion and bolus injection. Eur J Clin Pharmacol 38 (1990) 297-301
106. Claustrat B., Loisy C., Brun J., Beorchia S., Arnaud J.L., and Chazot G. Nocturnal plasma melatonin levels in migraine: a preliminary report. Headache 29 (1989) 241-244
107. Seabra M.L., Bignotto M., Pinto Jr. L.R., and Tufik S. Randomized, double-blind clinical trial, controlled with placebo, of the toxicology of chronic melatonin treatment. J Pineal Res 29 (2000) 193-200
108. Nishiyama K., Yasue H., Moriyama Y., Tsunoda R., Ogawa H., Yoshimura M., et al. Acute effects of melatonin administration on cardiovascular autonomic regulation in healthy men. Am Heart J 141 (2001) E9-E13
109. Gitto E., Romeo C., Reiter R.J., Impellizzeri P., Pesce C., Basile M., et al. Melatonin reduce oxidative stress in surgical neonates. J. Pediatric Surgery 39 (2004) 184-189
110. Gitto E., Reiter R.J., Cordano S.P., La Rosa M., Chiurazzi P., Trimarchi G., et al. Oxidative and inflammatory parameters in respiratory distress síndrome of preterm newborns: beneficial effects of melatonin. Am J Perinatol 21 (2004) 209-216
111. Gitto E., Reiter R.J., Amodio A., Cuzzocrea E., Sabatino G., Buonocore J., et al. Early indicators of chronic lung disease in preterm infants with respiratory distress syndrome and their inhibition by melatonin. J Pineal Res 36 (2004) 250-255
112. Dominguez-Rodriguez A., Abreu-Gonzalez P., Garcia-Gonzalez M.J., Kaski J.C., Reiter R.J., and Jimenez-Sosa A. A unicenter, randomized, double-blind, parallel-group, placebo-controlled study of Melatonin as an Adjunct in patients with acute myocaRdial Infarction undergoing primary Angioplasty The Melatonin Adjunct in the acute myocaRdial Infarction treated with Angioplasty (MARIA) trial: study design and rationale. Contemp Clin Trials 28 (2007) 532-539